Logo
CJC 1295 DAC (2mg x 10) Ipamorelin (2mg x 10)

CJC 1295 DAC (2mg x 10) Ipamorelin (2mg x 10)

Derma Filler Ltd

Research peptide product
  • No MHRA marketing authorisation is listed for this peptide combination bundle; it is not supplied as a licensed medicinal product in the UK.
  • Research peptide suppliers marketing the same CJC 1295 DAC (2mg x 10) and Ipamorelin (2mg x 10) bundle clearly label it as "for research use only" and "not for human consumption", reflecting common industry practice for such products.
  • Derma Filler Ltd is registered in the UK as a private limited company (Company No. 13088463) with a stated nature of business of retail sale via mail order houses or via internet, indicating its role as an online retailer rather than as a licensed pharmaceutical manufacturer.
CJC-1295 DAC and Ipamorelin peptide combination (lyophilized powder vials)

Description

CJC-1295 DAC (2mg x 10) Ipamorelin (2mg x 10) is a peptide combination bundle supplied by Derma Filler Ltd, consisting of 10 vials of CJC-1295 with DAC (2 mg per vial) and 10 vials of Ipamorelin (2 mg per vial). The product is presented as lyophilized peptide powder in glass vials and is offered as a research-only peptide combination for laboratory and in vitro experimentation. As with comparable products from other research suppliers, this type of bundle is typically used to investigate growth hormone–related pathways, pharmacokinetics and receptor biology in controlled experimental settings. It is not an MHRA-licensed medicine, not approved for therapeutic use, and is marketed as being for research purposes only and not for human or veterinary consumption.

Bnefits

  • Provides a matched combination of two widely researched growth hormone secretagogue–type peptides (CJC-1295 with DAC and Ipamorelin) in fixed 2 mg vial sizes for experimental design consistency.
  • Bundle format (10 x 2 mg CJC-1295 DAC vials and 10 x 2 mg Ipamorelin vials) allows parallel or sequential investigation of each peptide or their combined effects in research models.
  • Lyophilized powder presentation supports extended stability under appropriate refrigerated storage and flexibility in choosing reconstitution volumes for different assay designs.
  • Frequently used in research contexts to study growth hormone axis modulation, receptor binding, pharmacokinetic properties and related signalling pathways in vitro or in experimental systems.
  • Clearly positioned (by analogous suppliers of the same bundle) as a research and laboratory product, with labelling emphasising that it is not intended for human or veterinary use, helping laboratories comply with research-use-only frameworks.

Indications

  • Not an approved medicinal product; there are no licensed therapeutic indications.
  • Supplied and marketed for in vitro and laboratory research use only (for example, studies of growth hormone–related pathways, receptor interactions, pharmacokinetics and cellular signalling) by qualified professionals in appropriately equipped facilities.
  • Must not be used, advertised or supplied as a drug, food, cosmetic or dietary supplement, and must not be introduced into humans or animals.

Composition

  • CJC-1295 with DAC (Drug Affinity Complex) – synthetic peptide analogue of growth hormone–releasing hormone (GHRH); 2 mg lyophilized peptide per CJC-1295 DAC vial (10 vials in the bundle).
  • Ipamorelin – synthetic pentapeptide classified as a growth hormone secretagogue–type research peptide; 2 mg lyophilized peptide per Ipamorelin vial (10 vials in the bundle).
  • Additional excipients (e.g. bulking agents, stabilisers) are not specified by the seller and may vary by underlying peptide manufacturer.
  • Typical reference molecular data from research suppliers for these peptides include: CJC-1295 with DAC approximate molecular formula C165H269N47O46; Ipamorelin approximate molecular formula C38H49N9O5.

Formulation

  • Form: Lyophilized (freeze-dried) peptide powder in glass vials, intended to be reconstituted with a suitable sterile laboratory diluent (e.g. bacteriostatic water) for research use only.
  • Strength per vial: 2 mg CJC-1295 with DAC in each of 10 vials; 2 mg Ipamorelin in each of 10 vials.
  • Purity: Research suppliers of comparable peptide bundles typically state high peptide purity (often ≥98–99%) verified by analytical techniques such as HPLC and mass spectrometry, although specific assay values for this Derma Filler Ltd bundle are not published.
  • Intended use: Research and laboratory experimentation only; not formulated, packaged or authorised as a medicinal product for administration to humans or animals.

Packaging

  • Bundle containing a total of 20 glass vials: 10 vials labelled CJC-1295 DAC 2 mg and 10 vials labelled Ipamorelin 2 mg (exact vial labelling may vary).
  • Vials supplied as lyophilized powder with crimped or capped closures appropriate for laboratory reconstitution.
  • Outer packaging typically consists of a carton or protective container used for shipment from the online retailer; detailed carton artwork and any batch/lot labelling are not publicly specified.
  • Sold online via dermafillerltd.uk as a "Peptide Combination Special" often advertised with free shipping by the seller.

Usage

  • This product is sold for research and laboratory use only. It is not intended for human or veterinary use and must not be injected, ingested or otherwise introduced into humans or animals.
  • Handling and any reconstitution must only be performed by suitably trained and licensed laboratory professionals familiar with peptide handling, appropriate aseptic techniques and institutional safety procedures.
  • If reconstitution is performed for in vitro experiments, laboratories should follow their own validated protocols for selecting diluents, reconstitution volumes and working concentrations, in line with internal risk assessments and experimental design; no manufacturer-approved dosing or administration guidance exists for clinical use.
  • Use appropriate personal protective equipment (e.g. laboratory coat, gloves, eye protection) and work in a suitable laboratory environment when handling vials, powders and solutions.
  • Do not use this product as, or mislabel it as, a medicinal product, cosmetic, food or dietary supplement. All usage must remain within the bounds of research-only regulations that apply in the relevant jurisdiction.
  • Dispose of any unused material, reconstituted solutions and contaminated consumables as laboratory chemical/biological waste, following local institutional and regulatory requirements.

Contraindications

  • Contraindicated for any form of human or veterinary administration (e.g. injection, ingestion, topical use or inhalation); such use would fall outside the stated research-only designation.
  • Should not be handled by untrained or unauthorised individuals; use is restricted to qualified laboratory personnel in appropriate facilities.
  • Do not use if vials appear damaged, cracked, contaminated, discoloured or if labelling is missing or illegible.
  • Not to be used as an ingredient in compounded medicines, cosmetic products, foods or dietary supplements.
  • Laboratories should avoid use in experiments that conflict with institutional, national or international regulations governing research chemicals and peptides.

Adverse Effects

  • No safety profile for human or veterinary administration is established because the product is not intended or approved for such use.
  • As with many research chemicals and lyophilized peptide powders, potential laboratory hazards include eye, skin or respiratory tract irritation if material is mishandled (e.g. dust generation, spills); appropriate PPE and engineering controls should be used.
  • Accidental exposure (e.g. splashes to eyes or skin) should be managed according to standard laboratory first-aid protocols, including rinsing with water and seeking medical advice if irritation persists.
  • Improper storage or handling may degrade peptide integrity, potentially affecting experimental results and causing loss of research material rather than classical "adverse effects".
  • Any incidents or exposures in the laboratory should be documented and managed according to institutional health and safety policies.

Storage Conditions

  • Store vials in a refrigerator under controlled cold conditions (typically 2–8 °C) unless otherwise indicated on the vial label or accompanying documentation.
  • Keep vials in their original packaging or in a secondary container that protects them from light, moisture, and physical damage.
  • Avoid unnecessary temperature fluctuations and repeated freeze–thaw cycles of reconstituted solutions, as these may compromise peptide stability.
  • For long-term storage, many peptide suppliers recommend freezing lyophilized peptides at low temperatures (e.g. –20 °C) and storing any reconstituted solutions at 2–8 °C for a limited period as defined by internal laboratory validation; users should follow any product-specific guidance provided with the shipment.
  • Ensure that access to stored vials is restricted to authorised laboratory personnel and that inventory records (batch/lot, receipt date, storage location) are maintained according to institutional policies.

Duration

Not applicable. This is not a licensed medicinal product and no clinical treatment regimens or durations are established; it is supplied solely for laboratory and in vitro research use.

Onset

Not applicable in a clinical or therapeutic sense. In research contexts, CJC-1295 with DAC and Ipamorelin have been studied for their effects on growth hormone secretion and related pathways in experimental models, but these observations do not constitute approved clinical performance characteristics for this product.

Browse more Research peptide product

Top Treatments

Top Cities in the UK